Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Acquired by Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) on Oct. 11, 2023. Show more

Location: 80 W. Lancaster Avenue, Suite 300, Pennsylvania, 19333, US | Website: www.zynerba.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

901.4M

52 Wk Range

$N/A - $N/A

Previous Close

$1.30

Open

$1.30

Volume

N/A

Day Range

$1.30 - $1.30

Enterprise Value

0.00

Cash

159.3M

Avg Qtr Burn

N/A

Insider Ownership

6.07%

Institutional Own.

12.13%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zygel (ZYN002 CBD Gel) Details Epilepsy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zygel (ZYN002 CBD Gel) Details Autism spectrum disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.